Abiomed, Inc.

NasdaqGS:ABMD Stock Report

Market Cap: US$17.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abiomed Future Growth

Future criteria checks 1/6

Key information

-2.5%

Earnings growth rate

-2.0%

EPS growth rate

Medical Equipment earnings growth12.4%
Revenue growth rate13.1%
Future return on equity15.1%
Analyst coverage

Low

Last updatedn/a

Recent future growth updates

Recent updates

Abiomed's Impella low profile sheath gets FDA clearance

Oct 17

Abiomed: Correction Offers Good Buying Opportunity

Sep 28

U.S. FDA gives two approvals to Abiomed Impella heart pumps

Sep 16

Abiomed FQ1 2023 Earnings Preview

Aug 03

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

May 17

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Jan 24

Abiomed: Impella Will Continue To Drive Revenue Growth

Sep 10

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Jul 13

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Jun 08

Abiomed acquires preCARDIA a company targeting acute heart failure

Jun 01

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

May 06

Abiomed FQ4 2021 Earnings Preview

Apr 28

Earnings and Revenue Growth Forecasts

NasdaqGS:ABMD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20251,488262N/A4462
3/31/20241,265226N/A3603
3/31/20231,144269N/A2993
9/30/20221,074267217251N/A
6/30/20221,056218263298N/A
3/31/20221,032137250285N/A
12/31/20211,003133246293N/A
9/30/2021974149233282N/A
6/30/2021935154248298N/A
3/31/2021848226221275N/A
12/31/2020813200237275N/A
9/30/2020803208246285N/A
6/30/2020798159240282N/A
3/31/2020841203271315N/A
12/31/2019841245257299N/A
9/30/2019820221243284N/A
6/30/2019797258229270N/A
3/31/2019769259208252N/A
12/31/2018737222191238N/A
9/30/2018690190155220N/A
6/30/2018641165142203N/A
3/31/2018594112137193N/A
12/31/201754490103173N/A
9/30/20175059293151N/A
6/30/20174757770125N/A
3/31/20174455265115N/A
12/31/20164154869100N/A
9/30/2016386436992N/A
6/30/201635942N/A92N/A
3/31/201633038N/A77N/A
12/31/2015303126N/A73N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABMD's earnings are forecast to decline over the next 3 years (-2.5% per year).

Earnings vs Market: ABMD's earnings are forecast to decline over the next 3 years (-2.5% per year).

High Growth Earnings: ABMD's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ABMD's revenue (13.1% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: ABMD's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABMD's Return on Equity is forecast to be low in 3 years time (15.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/24 23:34
End of Day Share Price 2022/12/21 00:00
Earnings2022/09/30
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abiomed, Inc. is covered by 26 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lawrence NeiborBaird
Jan WaldBenchmark Company
Michael GormanBTIG